Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,586

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Signal integration by JNK and p38 MAPK pathways in cancer development

Open access
Wagner, Erwin F., Nebreda, Ángel R.·2009·Nature Reviews Cancer
DOI 10.1038/nrc2694
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc2694

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 152

  1. Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev. Cancer 4, 937–947 (2004). · DOI · Paper page
  2. Nebreda, A. R. & Porras, A. p38 MAP kinases: beyond the stress response. Trends Biochem. Sci. 25, 257–260 (2000). · DOI · Paper page
  3. Kyriakis, J. M. & Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807–869 (2001). · DOI · Paper page
  4. Karin, M. & Gallagher, E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57, 283–295 (2005). · DOI · Paper page
  5. Rincon, M. & Davis, R. J. Regulation of the immune response by stress-activated protein kinases. Immunol. Rev. 228, 212–224 (2009). · DOI · Paper page
  6. Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37–40 (2001). · DOI · Paper page
  7. Morrison, D. K. & Davis, R. J. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19, 91–118 (2003). · DOI · Paper page
  8. Avruch, J. MAP kinase pathways: the first twenty years. Biochim. Biophys. Acta. 1773, 1150–1160 (2007). · DOI · Paper page
  9. Gupta, S. et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15, 2760–2770 (1996). · DOI · Paper page
  10. Cuevas, B. D., Abell, A. N. & Johnson, G. L. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26, 3159–3171 (2007). · DOI · Paper page
  11. Bode, A. M. & Dong, Z. The functional contrariety of JNK. Mol. Carcinog. 46, 591–598 (2007). · DOI · Paper page
  12. Eferl, R. & Wagner, E. F. AP-1: a double-edged sword in tumorigenesis. Nature Rev. Cancer 3, 859–868 (2003). · DOI · Paper page
  13. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994). · DOI · Paper page
  14. Sanz, V., Arozarena, I. & Crespo, P. Distinct carboxy-termini confer divergent characteristics to the mitogen-activated protein kinase p38α and its splice isoform Mxi2. FEBS Lett. 474, 169–174 (2000). · DOI
  15. Ono, K. & Han, J. The p38 signal transduction pathway: activation and function. Cell Signal 12, 1–13 (2000). · DOI · Paper page
  16. Cuenda, A. & Rousseau, S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773, 1358–1375 (2007). · DOI · Paper page
  17. Mittelstadt, P. R., Salvador, J. M., Fornace, A. J. Jr & Ashwell, J. D. Activating p38 MAPK: new tricks for an old kinase. Cell Cycle 4, 1189–1192 (2005). · DOI
  18. Bulavin, D. V. & Fornace, A. J. Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92, 95–118 (2004). · DOI · Paper page
  19. Dolado, I. & Nebreda, A. R. Regulation of tumorigenesis by p38αMAP kinase. Topics in Current Genetics: Stress-Activated Protein Kinases 20, 99–128 (2008). · DOI
  20. Hui, L., Bakiri, L., Stepniak, E. & Wagner, E. F. p38a: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6, 2429–2433 (2007). · DOI · Paper page
  21. Sabapathy, K. et al. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15, 713–725 (2004). · DOI · Paper page
  22. Sabapathy, K. & Wagner, E. F. JNK2: a negative regulator of cellular proliferation. Cell Cycle 3, 1520–1523 (2004). · DOI
  23. Fuchs, S. Y., Dolan, L., Davis, R. J. & Ronai, Z. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 13, 1531–1535 (1996).
  24. Jaeschke, A. et al. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell 23, 899–911 (2006). · DOI · Paper page
  25. Das, M. et al. Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc. Natl Acad. Sci. USA 104, 15759–15764 (2007). This paper links the JNK pathway to p53-dependent senescence using a conditional · DOI
  26. Hochedlinger, K., Wagner, E. F. & Sabapathy, K. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene 21, 2441–2445 (2002). · DOI
  27. Ventura, J. J. et al. Chemical genetic analysis of the time course of signal transduction by JNK. Mol. Cell 21, 701–710 (2006). · DOI · Paper page
  28. Deng, Y., Ren, X., Yang, L., Lin, Y. & Wu, X. A JNK-dependent pathway is required for TNFα-induced apoptosis. Cell 115, 61–70 (2003). · DOI · Paper page
  29. Wang, L., Du, F. & Wang, X. TNF-α induces two distinct caspase-8 activation pathways. Cell 133, 693–703 (2008). · DOI · Paper page
  30. Huang, C., Rajfur, Z., Borchers, C., Schaller, M. D. & Jacobson, K. JNK phosphorylates paxillin and regulates cell migration. Nature 424, 219–223 (2003). · DOI · Paper page
  31. David, J. P., Sabapathy, K., Hoffmann, O., Idarraga, M. H. & Wagner, E. F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115, 4317–4325 (2002). · DOI · Paper page
  32. Rincon, M. et al. The JNK pathway regulates the in vivo deletion of immature CD4+CD8+thymocytes. J. Exp. Med. 188, 1817–1830 (1998). · DOI · Paper page
  33. Ambrosino, C. & Nebreda, A. R. Cell cycle regulation by p38 MAP kinases. Biol. Cell 93, 47–51 (2001). · DOI
  34. Thornton, T. M. & Rincon, M. Non-classical p38 MAP kinase functions: cell cycle checkpoints and survival. Int. J. Biol. Sci. 5, 44–51 (2009). · DOI · Paper page
  35. Wang, X. et al. Involvement of the MKK6–p38γ cascade in γ-radiation-induced cell cycle arrest. Mol. Cell Biol. 20, 4543–4552 (2000). · DOI · Paper page
  36. Han, J. & Sun, P. The pathways to tumor suppression via route p38. Trends Biochem. Sci. 32, 364–371 (2007). · DOI · Paper page
  37. Engel, F. B. et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19, 1175–1187 (2005). · DOI · Paper page
  38. Hui, L. et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway. Nature Genet. 39, 741–749 (2007). Genetically engineered mouse models show that p38α negatively regulates the proliferation of hepatocytes, fibroblasts and haematopoietic cells, as well as liver tumorigenesis. Downregulation of the JNK/JUN pathway has an important role in these effects of p38α. · DOI · Paper page
  39. Ventura, J. J. et al. p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nature Genet. 39, 750–758 (2007). This paper provides genetic evidence for the role of p38α in coordinating proliferation and differentiation of lung epithelial cells. As a consequence, p38α-deficient mice are highly sensitized to Kras -induced lung tumorigenesis. · DOI · Paper page
  40. Schindler, E. M. et al. p38δ Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res. 69, 4648–4655 (2009). · DOI
  41. Platanias, L. C. MAP kinase signaling pathways and hematologic malignancies. Blood 101, 4667–4679 (2003). · DOI · Paper page
  42. Lee, R. J. et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J. Biol. Chem. 274, 7341–7350 (1999). · DOI · Paper page
  43. Halawani, D., Mondeh, R., Stanton, L. A. & Beier, F. p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 23, 3726–3731 (2004). · DOI
  44. Ricote, M. et al. The p38 transduction pathway in prostatic neoplasia. J. Pathol. 208, 401–407 (2006). · DOI
  45. Recio, J. A. & Merlino, G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21, 1000–1008 (2002). · DOI
  46. Fan, L. et al. A novel role of p38α MAPK in mitotic progression independent of its kinase activity. Cell Cycle 4, 1616–1624 (2005). · doi:10.4161/cc.4.11.2125
  47. Neve, R. M., Holbro, T. & Hynes, N. E. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21, 4567–4576 (2002). · DOI
  48. Dolado, I. et al. p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11, 191–205 (2007). This paper shows that p38α negatively regulates the initiation of tumorigenesis by sensing the oncogene-induced accumulation of reactive oxygen species and triggering apoptosis. · DOI · Paper page
  49. Kaiser, R. A. et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J. Biol. Chem. 279, 15524–15530 (2004). · DOI · Paper page
  50. Nemoto, S., Xiang, J., Huang, S. & Lin, A. Induction of apoptosis by SB202190 through inhibition of p38β mitogen-activated protein kinase. J. Biol. Chem. 273, 16415–16420 (1998). · DOI · Paper page
  51. Silva, G., Cunha, A., Gregoire, I. P., Seldon, M. P. & Soares, M. P. The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38α MAPK isoform. J. Immunol. 177, 1894–1903 (2006). · DOI
  52. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nature Rev. Cancer 7, 834–846 (2007). · DOI · Paper page
  53. Comes, F. et al. A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ. 14, 693–702 (2007). · DOI
  54. Aouadi, M. et al. p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis. Stem Cells 24, 1399–1406 (2006). · DOI
  55. Schmelter, M., Ateghang, B., Helmig, S., Wartenberg, M. & Sauer, H. Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation. FASEB J. 20, 1182–1184 (2006). · DOI · Paper page
  56. Lluis, F., Perdiguero, E., Nebreda, A. R. & Muñoz-Canoves, P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 16, 36–44 (2006). · DOI · Paper page
  57. Perdiguero, E. & Muñoz-Canoves, P. Transcriptional regulation by the p38 MAPK signalling pathway in mammalian cells. Topics in Current Genetics: Stress-Activated Protein Kinases 20, 51–79 (2008). · DOI
  58. Forte, G. et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 24, 23–33 (2006). · DOI · Paper page
  59. Perdiguero, E. et al. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38α in abrogating myoblast proliferation. EMBO J. 26, 1245–1256 (2007). · DOI
  60. Puri, P. L. et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 14, 574–584 (2000). · DOI · Paper page
  61. Finn, G. J., Creaven, B. S. & Egan, D. A. Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. Biochem. Pharmacol. 67, 1779–1788 (2004). · doi:10.1016/j.bcp.2004.01.014
  62. Ordonez-Moran, P. et al. RhoA–ROCK and p38MAPK–MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol. 183, 697–710 (2008). · DOI
  63. Hazzalin, C. A. et al. p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ATF-2 phosphorylation are insufficient. Curr. Biol. 6, 1028–1031 (1996). · DOI · Paper page
  64. Nemoto, S., Sheng, Z. & Lin, A. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol. Cell Biol. 18, 3518–3526 (1998). · DOI · Paper page
  65. Tourian, L. Jr, Zhao, H. & Srikant, C. B. p38α, but not p38β, inhibits the phosphorylation and presence of c-FLIPS in DISC to potentiate Fas-mediated caspase-8 activation and type I apoptotic signaling. J. Cell Sci. 117, 6459–6471 (2004). · DOI
  66. Wada, T. et al. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ. 15, 89–93 (2008). · DOI
  67. Cheung, P. C., Campbell, D. G., Nebreda, A. R. & Cohen, P. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J. 22, 5793–5805 (2003). · DOI · Paper page
  68. Muniyappa, H. & Das, K. C. Activation of c-Jun N.-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK3–MKK7-dependent mechanism. Cell Signal 20, 675–683 (2008). · DOI
  69. Heinrichsdorff, J., Luedde, T., Perdiguero, E., Nebreda, A. R. & Pasparakis, M. p38α MAPK inhibits JNK activation and collaborates with IκB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep. 9, 1048–1054 (2008). · DOI
  70. Kamata, H. et al. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649–661 (2005). The paper shows that hepatocytes lacking IKKβ show reduced JNK phosphatase activity, leading to sustained JNK1 activation and increased liver carcinogenesis. · DOI · Paper page
  71. Papa, S. et al. Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2. Nature Cell Biol. 6, 146–153 (2004). · DOI · Paper page
  72. Papa, S. et al. Gadd45β promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J. Clin. Invest. 118, 1911–1923 (2008). · DOI
  73. Hasselblatt, P., Rath, M., Komnenovic, V., Zatloukal, K. & Wagner, E. F. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc. Natl Acad. Sci. USA 104, 17105–17110 (2007). · DOI
  74. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977–990 (2005). References 81–83 clearly show that the JNK pathway induces cell death in Con A-induced hepatitis and cytokine-driven hepatocarcinogenesis, whereas JUN/AP1 is hepatoprotective in the Con A model of hepatitis and antagonizes JNK function. · DOI · Paper page
  75. Das, M. et al. Induction of hepatitis by JNK-mediated expression of TNF-α. Cell 136, 249–260 (2009). · DOI
  76. Kaser, A. et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134, 743–756 (2008). · DOI · Paper page
  77. Hammaker, D. R., Boyle, D. L., Inoue, T. & Firestein, G. S. Regulation of the JNK pathway by TGF-β activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res. Ther. 9, R57 (2007). · DOI
  78. Ricci, R. et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306, 1558–1561 (2004). · DOI · Paper page
  79. Bachelor, M. A. & Bowden, G. T. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin. Cancer Biol. 14, 131–138 (2004). · DOI · Paper page
  80. Timoshenko, A. V., Chakraborty, C., Wagner, G. F. & Lala, P. K. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br. J. Cancer 94, 1154–1163 (2006). · DOI
  81. Xu, K. & Shu, H. K. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res. 67, 6121–6129 (2007). · DOI
  82. Kumar, S., Boehm, J. & Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Rev. Drug Discov. 2, 717–726 (2003). · DOI · Paper page
  83. Clark, A. R., Dean, J. L. & Saklatvala, J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett. 546, 37–44 (2003). · DOI · Paper page
  84. Kim, C. et al. The kinase p38α serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nature Immunol. 9, 1019–1027 (2008). · DOI · Paper page
  85. Kang, Y. J. et al. Macrophage deletion of p38α partially impairs lipopolysaccharide-induced cellular activation. J. Immunol. 180, 5075–5082 (2008). References 93 and 94 provide genetic evidence for the regulation of cytokine production and inflammatory responses by p38α in myeloid and epithelial cells. · DOI
  86. Beardmore, V. A. et al. Generation and characterization of p38β (MAPK11) gene-targeted mice. Mol. Cell. Biol. 25, 10454–10464 (2005). · DOI · Paper page
  87. O'Keefe, S. J. et al. Chemical genetics define the roles of p38α and p38β in acute and chronic inflammation. J. Biol. Chem. 282, 34663–34671 (2007). · DOI
  88. Emerling, B. M. et al. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol. Cell Biol. 25, 4853–4862 (2005). · DOI · Paper page
  89. Hsieh, Y. H. et al. p38 mitogen-activated protein kinase pathway is involved in protein kinase Cα-regulated invasion in human hepatocellular carcinoma cells. Cancer Res. 67, 4320–4327 (2007). · DOI
  90. Junttila, M. R. et al. p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26, 5267–5279 (2007). · DOI
  91. Demuth, T. et al. MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol. Cancer Ther. 6, 1212–1222 (2007). · DOI
  92. Matsuo, Y. et al. Involvement of p38α mitogen-activated protein kinase in lung metastasis of tumor cells. J. Biol. Chem. 281, 36767–36775 (2006). · DOI
  93. Loesch, M. & Chen, G. The p38 MAPK stress pathway as a tumor suppressor or more? Front. Biosci. 13, 3581–3593 (2008). · DOI
  94. Hickson, J. A. et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 66, 2264–2270 (2006). · DOI
  95. Vander Griend, D. J. et al. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 65, 10984–10991 (2005). · DOI
  96. Kim, M. S., Lee, E. J., Kim, H. R. & Moon, A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 63, 5454–5461 (2003).
  97. Dreissigacker, U. et al. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal. 18, 1156–1168 (2006). · DOI
  98. McMullen, M. E., Bryant, P. W., Glembotski, C. C., Vincent, P. A. & Pumiglia, K. M. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J. Biol. Chem. 280, 20995–21003 (2005). · DOI
  99. Rousseau, S. et al. CXCL12 and C5a trigger cell migration via a PAK1/2–p38α MAPK–MAPKAP–K2–HSP27 pathway. Cell Signal 18, 1897–1905 (2006). · DOI
  100. Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biol. 8, 1369–1375 (2006). · DOI · Paper page
  101. Kobayashi, M., Nishita, M., Mishima, T., Ohashi, K. & Mizuno, K. MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced actin remodeling and cell migration. EMBO J. 25, 713–726 (2006). · DOI · Paper page
  102. Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181–192 (2003). · DOI · Paper page
  103. Sakurai, T., Maeda, S., Chang, L. & Karin, M. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl Acad. Sci. USA 103, 10544–10551 (2006). · DOI · Paper page
  104. Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E. & Wagner, E. F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118, 3943–3953 (2008). References 112 and 113 describe the molecular functions of JNK1 and JNK2 in mouse and human liver cancer cells using mouse liver carcinogenesis models and human liver cancer cell lines. · DOI · Paper page
  105. Chen, F. & Castranova, V. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle 8, 1145–1147 (2009). · DOI
  106. She, Q. B., Chen, N., Bode, A. M., Flavell, R. A. & Dong, Z. Deficiency of c-Jun-NH2-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62, 1343–1348 (2002).
  107. Chen, N. et al. Suppression of skin tumorigenesis in c-Jun NH2-terminal kinase-2-deficient mice. Cancer Res. 61, 3908–3912 (2001).
  108. Nateri, A. S., Spencer-Dene, B. & Behrens, A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437, 281–285 (2005). · DOI · Paper page
  109. Sancho, R. et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J. (2009). · DOI
  110. Hasselblatt, P., Gresh, L., Kudo, H., Guinea-Viniegra, J. & Wagner, E. F. The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice. Oncogene 27, 6102–6109 (2008). · doi:10.1038/onc.2008.211
  111. Tong, C. et al. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am. J. Pathol. 171, 297–303 (2007). · DOI
  112. Shibata, W. et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 68, 5031–5039 (2008). · DOI
  113. Hess, P., Pihan, G., Sawyers, C. L., Flavell, R. A. & Davis, R. J. Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts. Nature Genet. 32, 201–205 (2002). · DOI · Paper page
  114. Bulavin, D. V. et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet. 31, 210–215 (2002). · DOI · Paper page
  115. Brancho, D. et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 17, 1969–1978 (2003). · DOI · Paper page
  116. Bulavin, D. V. et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a–p19Arf pathway. Nature Genet. 36, 343–350 (2004). · DOI · Paper page
  117. Demidov, O. N. et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26, 2502–2506 (2007). References 125 and 126 provide in vivo evidence for the role of PPM1D, a negative regulator of p38α, in mammary gland tumorigenesis. · DOI
  118. Tront, J. S., Hoffman, B. & Liebermann, D. A. Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res. 66, 8448–8454 (2006). · DOI
  119. Yang, Y. A., Zhang, G. M., Feigenbaum, L. & Zhang, Y. E. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9, 445–457 (2006). · DOI
  120. Breitwieser, W. et al. Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev. 21, 2069–2082 (2007). · DOI
  121. Shi, Y. et al. Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. Mol. Cell. Biol. 23, 7732–7741 (2003). · DOI
  122. Whitmarsh, A. J. & Davis, R. J. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26, 3172–3184 (2007). · DOI
  123. Johnson, G. L. & Nakamura, K. The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease. Biochim. et Biophys. Acta 1773, 1341–1348 (2007). · DOI · Paper page
  124. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007). · DOI · Paper page
  125. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008). · DOI · Paper page
  126. Chang, Q. et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J. Hepatol. 50, 323–333 (2009). · DOI
  127. Yoshida, S. et al. The c-Jun NH2-terminal kinase 3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J. Hum. Genet. 46, 182–187 (2001). · DOI
  128. Vivanco, I. et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11, 555–569 (2007). This paper shows that PTEN loss leads to AKT activation and to increased JNK activity in human cancer cell lines and clinical prostate samples. · DOI · Paper page
  129. Ouyang, X. et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68, 2132–2144 (2008). · DOI
  130. Konishi, N. et al. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Clin. Cancer Res. 14, 4408–4416 (2008). · DOI · Paper page
  131. Liu, J. et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 323, 1218–1222 (2009). · DOI
  132. Li, J. et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nature Genet. 31, 133–134 (2002). · DOI · Paper page
  133. Yu, W. et al. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26, 1178–1187 (2007). · DOI
  134. Iyoda, K. et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97, 3017–3026 (2003). · DOI
  135. Elenitoba-Johnson, K. S. et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc. Natl Acad. Sci. USA 100, 7259–7264 (2003). · DOI
  136. Greenberg, A. K. et al. Selective p38 activation in human non-small cell lung cancer. Am. J. Respir. Cell. Mol. Biol. 26, 558–564 (2002). · DOI · Paper page
  137. Esteva, F. J. et al. Prognostic significance of phosphorylated p38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100, 499–506 (2004). · DOI
  138. Pomerance, M., Quillard, J., Chantoux, F., Young, J. & Blondeau, J. P. High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J. Pathol. 209, 298–306 (2006). · DOI
  139. Mayer, R. J. & Callahan, J. F. p38 MAP kinase inhibitors: a future therapy for inflammatory diseases. Drug Discovery Today 3, 49–54 (2006). · DOI
  140. Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175–189 (2007). This paper shows that the p38-activated kinase MK2 is important for the survival of cancer cells treated with chemotherapeutic drugs that induce DNA damage. · DOI · Paper page
  141. Vaidya, A. A., Sharma, M. B. & Kale, V. P. Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them. Cancer Biol. Ther. 7, 1232–1240 (2008). · doi:10.4161/cbt.7.8.6262
  142. Olson, J. M. & Hallahan, A. R. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol. Med. 10, 125–129 (2004). · DOI · Paper page
  143. Bogoyevitch, M. A. & Arthur, P. G. Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim. Biophys. Acta 1784, 76–93 (2008). · DOI
  144. Salh, B. c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin. Ther. Targets. 11, 1339–1353 (2007). · DOI
  145. Yao, K. et al. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1. FEBS Lett. 583, 2208–2212 (2009). · DOI
  146. Borsello, T. et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nature Med. 9, 1180–1186 (2003). · DOI · Paper page
  147. Sabio, G. et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322, 1539–1543 (2008). · DOI · Paper page
  148. Adams, R. H. et al. Essential role of p38α MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell 6, 109–116 (2000). · DOI · Paper page
  149. Mudgett, J. S. et al. Essential role for p38α mitogen-activated protein kinase in placental angiogenesis. Proc. Natl Acad. Sci. USA 97, 10454–10459 (2000). · DOI · Paper page
  150. Tamura, K. et al. Requirement for p38α in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 102, 221–231 (2000). · DOI · Paper page
  151. Sabio, G. et al. p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J. 24, 1134–1145 (2005). · DOI · Paper page
  152. Sumara, G. et al. Regulation of PKD by the MAPK p38d in insulin secretion and glucose homeostasis. Cell 136, 235–248 (2009). · DOI · Paper page

Cited by

See all 2,586

Metadata

Authors
Wagner, E. F., & Nebreda, Á. R.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2009-08
Volume
9
Issue
8
Pages
537-549
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc2694
OpenAlex
W2084472730
Cited by
2,586
References
12
FWCI
6.52
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Signal integration by JNK and p38 MAPK pathways in cancer development. https://app.cochat.ai/papers/10.1038/nrc2694
The paper
Wagner, E. F., & Nebreda, Á. R. (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews Cancer. https://doi.org/10.1038/nrc2694

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.